The ratio of surviving EGFR-mutated H1975 cells and HCC827 cells was decreased from 17.6−25.6% (10 μM TKIs) to 1.7%−13.6% (10 μM TKIs + 3.35−6.71 μM of TP4) and 47.1−50.7% (1 μM TKIs) to 3%−25.5% (1 μM TKIs + 3.35−6.71 μM of TP4) (Figure 1E,F), suggesting that these combinations may be considered as a potential therapeutic strategy for EGFR-mutated NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.